{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05451212",
            "orgStudyIdInfo": {
                "id": "CAB-MuSK-101"
            },
            "organization": {
                "fullName": "Cabaletta Bio",
                "class": "INDUSTRY"
            },
            "briefTitle": "Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis",
            "officialTitle": "A Phase 1, Open-label, Safety and Dose-finding Study of Autologous Muscle-specific Tyrosine Kinase Chimeric Autoantibody Receptor T Cells (MuSK-CAART) in Subjects With Anti-MuSK-antibody-positive Myasthenia Gravis",
            "therapeuticArea": [
                "Other"
            ],
            "study": "open-label-study-to-evaluate-the-safety-of-various-dosing-regimens-of-musk-caart-for-musk-myasthenia-gravis"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-11-23",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2028-10",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-10",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-06-30",
            "studyFirstSubmitQcDate": "2022-07-05",
            "studyFirstPostDateStruct": {
                "date": "2022-07-11",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-19",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-22",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Cabaletta Bio",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Muscle-specific tyrosine kinase (MuSK) myasthenia gravis (MG) is a rare but potentially severe disease, in which patients develop pathogenic autoantibodies that specifically target the MuSK protein in the neuromuscular junction. This phase 1 study is being conducted to evaluate the safety of various dosing regimens of an investigational cell therapy, MuSK-CAART, that can be given to patients with anti-MuSK antibody positive Myasthenia Gravis (MuSK MG), who have active disease. Various dosing regimens of MuSK-CAART alone, in combination with cyclophosphamide (CY), and in combination with CY and fludarabine (FLU) will be evaluated. Treatment with MuSK-CAART may potentially lead to complete and durable remission of disease."
        },
        "conditionsModule": {
            "conditions": [
                "MuSK Myasthenia Gravis"
            ],
            "keywords": [
                "CAAR-T (Chimeric Autoantibody Receptor T Cells) Therapy",
                "CAR-T (Chimeric Antigen Receptor T Cells) Therapy",
                "Cell Therapy",
                "Autoimmune Disease",
                "Autoimmunity",
                "Immunotherapy, Adoptive",
                "Immune System Diseases",
                "Myasthenia Gravis (MG)",
                "Muscle-specific tyrosine kinase (MuSK)",
                "Muscle Weakness",
                "Neuromuscular Diseases",
                "Musculoskeletal Diseases"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 24,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "MuSK-CAART",
                    "type": "EXPERIMENTAL",
                    "description": "Cohort A: Infusion of MuSK-CAART at various dose levels with or without pre-treatment (6 groups planned).\n\nCohort B: Infusion of MuSK-CAART at the dose regimen selected from Part A.",
                    "interventionNames": [
                        "Biological: MuSK-CAART"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "MuSK-CAART",
                    "description": "Intravenous infusion of MuSK-CAART at different doses. Subjects may also receive MuSK-CAART following pre-treatment with CY, or CY plus FLU.",
                    "armGroupLabels": [
                        "MuSK-CAART"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Adverse events",
                    "description": "Incidence of adverse events (AEs), including dose-limiting toxicities (DLTs) and AEs that are related to MuSK-CAART.",
                    "timeFrame": "3 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Total MuSK-CAART positive cells",
                    "description": "Total MuSK-CAART positive cells for each manufacturing run.",
                    "timeFrame": "Baseline"
                },
                {
                    "measure": "Percent of CAAR-transduced cells",
                    "description": "Percent of total cells for infusion that are CAAR (Chimeric Autoantibody Receptor)-transduced cells.",
                    "timeFrame": "Baseline"
                },
                {
                    "measure": "Cellular kinetics profile of MuSK-CAART",
                    "description": "Cellular kinetics profile of MuSK-CAART after infusion.",
                    "timeFrame": "Up to 36 months"
                },
                {
                    "measure": "Change in MuSK autoantibody titer",
                    "description": "Change in MuSK autoantibody titer compared to pre-infusion visit by clinically validated assay.",
                    "timeFrame": "Up to 36 months"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Use of Concomitant Therapies",
                    "description": "Frequency and dose of concomitant therapies.",
                    "timeFrame": "Up to 36 months"
                },
                {
                    "measure": "Measurement of Clinical Symptoms using MG-ADL",
                    "description": "Measurement of clinical symptoms using the Myasthenia Gravis Activities of Daily Living (MG-ADL) assessment.",
                    "timeFrame": "Up to 36 months"
                },
                {
                    "measure": "Measurement of Clinical Symptoms using QMG",
                    "description": "Measurement of clinical symptoms using the Quantitative Myasthenia Gravis (QMG) assessment.",
                    "timeFrame": "Up to 36 months"
                },
                {
                    "measure": "Measurement of Clinical Symptoms using MGC",
                    "description": "Measurement of clinical symptoms using the Myasthenia Gravis Composite (MGC) assessment.",
                    "timeFrame": "Up to 36 months"
                },
                {
                    "measure": "Measurement of Quality of Life (QoL) using MG-QOL-15r",
                    "description": "Measurement of Quality of Life using the MG-QOL-15r (Myasthenia Gravis Qualify of Life 15-item scale, revised) questionnaire.",
                    "timeFrame": "Up to 36 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Confirmed diagnosis of MuSK-type MG with at least 1 prior positive anti-MuSK antibody test.\n* History of a negative anti-AChR (acetylcholine receptor) antibody test.\n* Positive anti-MuSK antibody test at screening\n* MG severity Class I to IVa on the MGFA (Myasthenia Gravis Foundation of America) Clinical Classification\n\nExclusion Criteria:\n\n* Rituximab in the last 12 months.\n* Prednisone \\> 0.25mg/kg/day \\[in Part A\\]\n* Other autoimmune disorder requiring immunosuppressive therapies.\n* Investigational treatment for MG in the past 12 weeks.\n* Absolute lymphocyte count \\< 500/\u00b5L at screening.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Cabaletta Bio",
                    "role": "CONTACT",
                    "phone": "+1 267 759 3100",
                    "phoneExt": "4444",
                    "email": "clinicaltrials@cabalettabio.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Medical Director",
                    "affiliation": "Cabaletta Bio",
                    "role": "STUDY_CHAIR"
                }
            ],
            "locations": [
                {
                    "facility": "UC Irvine, Department of Neurology",
                    "status": "RECRUITING",
                    "city": "Orange",
                    "state": "California",
                    "zip": "92868",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Alpha Clinic",
                            "role": "CONTACT",
                            "phone": "949-824-3990",
                            "email": "alphaclinic@uci.edu"
                        },
                        {
                            "name": "Ali Habib, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.78779,
                        "lon": -117.85311
                    }
                },
                {
                    "facility": "UC Davis, Department of Neurology",
                    "status": "RECRUITING",
                    "city": "Sacramento",
                    "state": "California",
                    "zip": "95817",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Joshua Valdez",
                            "role": "CONTACT",
                            "phone": "916-734-7707",
                            "email": "joavaldez@ucdavis.edu"
                        },
                        {
                            "name": "David Richman, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.58157,
                        "lon": -121.4944
                    }
                },
                {
                    "facility": "University of Kansas Medical Center",
                    "status": "RECRUITING",
                    "city": "Kansas City",
                    "state": "Kansas",
                    "zip": "66160",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Andrew J Heim",
                            "role": "CONTACT",
                            "phone": "913-945-9926",
                            "email": "aheim2@kumc.edu"
                        },
                        {
                            "name": "Mazen Dimachkie, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.11417,
                        "lon": -94.62746
                    }
                },
                {
                    "facility": "University of North Carolina at Chapel Hill",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Chapel Hill",
                    "state": "North Carolina",
                    "zip": "27599",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.9132,
                        "lon": -79.05584
                    }
                },
                {
                    "facility": "Oregon Health & Science University (OHSU)",
                    "status": "RECRUITING",
                    "city": "Portland",
                    "state": "Oregon",
                    "zip": "97239",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Katie Lewis",
                            "role": "CONTACT",
                            "phone": "503-494-7394",
                            "email": "lewiskat@ohsu.edu"
                        },
                        {
                            "name": "Nizar Chahin, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 45.52345,
                        "lon": -122.67621
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009157",
                    "term": "Myasthenia Gravis"
                },
                {
                    "id": "D000018908",
                    "term": "Muscle Weakness"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009135",
                    "term": "Muscular Diseases"
                },
                {
                    "id": "D000009140",
                    "term": "Musculoskeletal Diseases"
                },
                {
                    "id": "D000020879",
                    "term": "Neuromuscular Manifestations"
                },
                {
                    "id": "D000009461",
                    "term": "Neurologic Manifestations"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                },
                {
                    "id": "D000020361",
                    "term": "Paraneoplastic Syndromes, Nervous System"
                },
                {
                    "id": "D000009423",
                    "term": "Nervous System Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000010257",
                    "term": "Paraneoplastic Syndromes"
                },
                {
                    "id": "D000020274",
                    "term": "Autoimmune Diseases of the Nervous System"
                },
                {
                    "id": "D000019636",
                    "term": "Neurodegenerative Diseases"
                },
                {
                    "id": "D000020511",
                    "term": "Neuromuscular Junction Diseases"
                },
                {
                    "id": "D000009468",
                    "term": "Neuromuscular Diseases"
                },
                {
                    "id": "D000001327",
                    "term": "Autoimmune Diseases"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12112",
                    "name": "Myasthenia Gravis",
                    "asFound": "Myasthenia Gravis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12097",
                    "name": "Musculoskeletal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M4629",
                    "name": "Autoimmune Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M20944",
                    "name": "Muscle Weakness",
                    "asFound": "Myasthenia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M13204",
                    "name": "Paresis",
                    "relevance": "LOW"
                },
                {
                    "id": "M4554",
                    "name": "Asthenia",
                    "relevance": "LOW"
                },
                {
                    "id": "M12411",
                    "name": "Neuromuscular Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12092",
                    "name": "Muscular Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M22619",
                    "name": "Neuromuscular Manifestations",
                    "relevance": "LOW"
                },
                {
                    "id": "M12404",
                    "name": "Neurologic Manifestations",
                    "relevance": "LOW"
                },
                {
                    "id": "M16355",
                    "name": "Syndrome",
                    "relevance": "LOW"
                },
                {
                    "id": "M13170",
                    "name": "Paraneoplastic Syndromes",
                    "relevance": "LOW"
                },
                {
                    "id": "M22160",
                    "name": "Paraneoplastic Syndromes, Nervous System",
                    "relevance": "LOW"
                },
                {
                    "id": "M12367",
                    "name": "Nervous System Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M22094",
                    "name": "Autoimmune Diseases of the Nervous System",
                    "relevance": "LOW"
                },
                {
                    "id": "M21558",
                    "name": "Neurodegenerative Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M22297",
                    "name": "Neuromuscular Junction Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T3973",
                    "name": "Myasthenia Gravis",
                    "asFound": "Myasthenia Gravis",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC05",
                    "name": "Musculoskeletal Diseases"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M2853",
                    "name": "Immunomodulating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4625",
                    "name": "Autoantibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                },
                {
                    "id": "T22",
                    "name": "Tyrosine",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "AA",
                    "name": "Amino Acids"
                }
            ]
        }
    },
    "hasResults": false
}